by Andrii Buvailo, PhD
In October, Biohub, the Chan Zuckerberg science organization, expanded its Virtual Biology Initiative to $1.8 billion. The money pays for open, standardized data to train virtual cells: AI models that …
Read More
by BiopharmaTrend , Roman Kasianov, Anastasiia Rohozianska, Andrii Buvailo, PhD
Latest changes · October 30, 2026 Biohub’s data push hit $1.8B with DOE, NIH, Google DeepMind, Isomorphic and Meta joining; commercial funders get a one-year head start on the data. One …
Read More
by Andrii Buvailo, PhD
Anthropic filed for its IPO with the SEC on Monday, and its S-1 shows that 9 of the 10 largest pharmaceutical companies in the Fortune 500 each spent at least …
Read More
by Andrii Buvailo, PhD
AI drug discovery has moved from platform pitches to clinical tests. One recent sign: in October 2026, Iambic Therapeutics raised $150 million in a Nasdaq IPO, saying in its filing …
Read More
by Andrii Buvailo, PhD
With Science Foundries, launched today, the R&D software company moves from helping scientists with individual tasks to managing entire scientific processes with teams of AI agents. The launch builds on …
Read More
by Andrii Buvailo, PhD
Generating drug candidate ideas has become inexpensive, and the supply of hypotheses now exceeds any organization’s capacity to evaluate them. Schrödinger’s answer, launched at the end of July, is Bunsen: …
Read More
